Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

@article{Maki2007RandomizedPI,
  title={Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].},
  author={Robert G Maki and J. Kyle Wathen and Shreyaskumar Patel and Dennis A. Priebat and Scott H. Okuno and Brian L Samuels and Michael P. Fanucchi and David C. Harmon and Scott M. Schuetze and Denise K Reinke and Peter F. Thall and Robert S Benjamin and Laurence H. Baker and Martee L. Hensley},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 19},
  pages={2755-63}
}
PURPOSE Gemcitabine as a single agent and the combination of gemcitabine and docetaxel have activity in patients with metastatic soft tissue sarcoma. To determine if the addition of docetaxel to gemcitabine improved clinical outcome of patients with metastatic soft tissue sarcomas, we compared a fixed dose rate infusion of gemcitabine versus a lower dose of gemcitabine with docetaxel. PATIENTS AND METHODS In this open-label phase II clinical trial, the primary end point was tumor response… CONTINUE READING
Highly Influential
This paper has highly influenced 13 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS